MedTrace Logo

Myrbetriq™ (Mirabegron) to Improve Disordered Sleep in Subjects With Lower Urinary Tract Symptoms (LUTS)

NCT02410135 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 34

Last updated 2019-05-09

No results posted yet for this study

Summary

The objective of this exploratory pilot study is to assess whether Mirabegron (Myrbetriq™) will improve the quality of sleep and Lower Urinary Tract Symptoms (LUTS) in men and women presenting with LUTS and disordered sleep.

Conditions

  • Lower Urinary Tract Symptoms
  • Nocturia

Interventions

DRUG

Mirabegron

25 mg PO per day for four weeks. if tolerated then uptitrated to 50 mg PO per day for the remaining 8 weeks

Sponsors & Collaborators

  • Astellas Scientific & Medical Affairs, Inc.

    collaborator INDUSTRY

  • Sisters of the Third Order of St. Francis

    collaborator OTHER

  • Southern Illinois University

    lead OTHER

Principal Investigators

  • Kevin McVary, MD · Southern Illinois University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02410135 on ClinicalTrials.gov